Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulmatrix Inc PULM

Healthcare
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as... see more

Recent & Breaking News (NDAQ:PULM)

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

PR Newswire July 11, 2023

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

PR Newswire June 15, 2023

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

PR Newswire May 24, 2023

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

PR Newswire May 12, 2023

Pulmatrix Supports World Asthma Day 2023

PR Newswire May 2, 2023

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

PR Newswire March 30, 2023

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

PR Newswire February 6, 2023

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

PR Newswire January 25, 2023

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

PR Newswire January 23, 2023

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

PR Newswire January 4, 2023

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire November 10, 2022

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

PR Newswire September 26, 2022

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire August 8, 2022

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

PR Newswire July 12, 2022

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire May 12, 2022

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

PR Newswire March 29, 2022

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

PR Newswire March 21, 2022

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

PR Newswire March 17, 2022

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

PR Newswire March 1, 2022

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

PR Newswire February 24, 2022